The management of a pharmaceutical applications company is looking for investor to finance further growth in exchange for a stake in the capital in the company. This company is a potential leader in its market niche and plans to gain a recognizable market position in its sector in the coming years. They started development of the technology 5 years ago and it has already developed it to a viable commercial solution.
Approximately 4 years ago, the company raised capital of 5M EUR from North American investment fund, which allowed the company to research and develop the current solution. Currently, the company launched second investment round and is looking for suited investors which would help and enable full commercialization of its technology and turnover growth.
The company for sale is a young and dynamic company, focused on recombinant protein expression technology. The company holds an already validated, protected and awarded technology allowing for substantial improvement in levels of recombinant protein production.
Recombinant human proteins, which are the key functional component in a wide array of pharmaceutical products and applications, hold a large potential as the market has already a multibillion dollar potential. Commercialization of the products is executed through an innovative licensing model, mitigating risks and maximizing return for the company.
He company headquarters are located in the Western Europe, but an office aimed at business development has already been established in the U.S., successfully operating ever since. The company has a team of more than 15 experienced and dedicated people – the team is constantly growing. The company has already established successful partnerships with big pharma and biotech companies.
Contact us to get details about this pharmaceutical applications manufacturer in Western Europe for sale
The company has developed a novel technology for improved production of complex, human proteins for pharmaceutical applications. This innovative process results in significant yield increases and production cost savings. The technology is highly suitable for production of biosimilars, the follow-on versions of original biological medicines, for which cost efficiency is essential in development and commercialization. The process also allows production of difficult proteins at commercially viable levels.
The client portfolio of the company includes mainly:
The business plan of the company projects the turnover of the company to soar and reach more than 15 M EUR per year after full commercialization though license provision in 5 years timespan. The profitability (EBITDA) should reach 60 – 75% of the turnover. The risk of lowering revenues is minimized by licenses paid upfront strategy - clients are granted a (multi) product license without any royalty obligation.
Please feel free to ask for more information about this pharmaceutical applications manufacturer in Western Europe for sale. If this company does not match your preferences, ask for our other pharmaceutical companies open for a sale. We know the pharmaceutical industry. If you are looking for other pharmaceutical business for sale, please visit the section pharmaceutical companies for sale. If you are looking to sell your pharmaceutical business or you know about the pharmaceutical company for sale, please visit the section pharmaceutical companies wanted.